Abstract
Background: Intradialytic hypotension (IDH) is common and is associated with increased morbidity and mortality in chronic hemodialysis patients. A higher dialysis ‘dose' may generate transient intradialytic osmotic gradients, predisposing to intracellular fluid shifts and resulting in hypotension. Study Design: We performed a post hoc analysis of the HEMO study, a multicenter trial that randomized chronic hemodialysis patients to high versus standard Kt/V and higher versus lower membrane flux. In order to achieve dose targets, per protocol, adjustments were made in membrane efficiency, blood flow or dialysate flow before changing session length. Detailed hemodynamic and urea kinetic modeling data were abstracted from 1,825 individuals. The primary outcome was the occurrence of hypotensive events necessitating clinical intervention (saline infusion, lowering of ultrafiltration rate or reduced blood flow). Results: Intradialytic hypotensive events occurred more frequently in the higher-Kt/V group (18.3 vs. 16.8%; p < 0.001). Participants randomized to higher-target Kt/V had a greater adjusted risk of IDH than those randomized to standard Kt/V [odds ratio (OR) 1.12; 95% confidence interval (CI) 1.01-1.25]. Higher vs. lower dialyzer mass transfer-area coefficient for urea and rate of urea removal were associated with greater adjusted odds of IDH (OR 1.15; 95% CI 1.04-1.27 and OR 1.05; 95% CI 1.04-1.06 per mg/dl/h, respectively). Conclusions: Higher dialysis dose, at relatively constrained treatment times, may associate with an increased risk of IDH. These findings support the possibility that rapidity of intradialytic reductions in plasma osmolality may play an important role in mediating hemodynamic instability during dialysis.
References
1.
Bos WJ, Bruin S, van Olden RW, Keur I, Wesseling KH, Westerhof N, Krediet RT, Arisz LA: Cardiac and hemodynamic effects of hemodialysis and ultrafiltration. Am J Kidney Dis 2000;35:819-826.
2.
Boon D, van Montfrans GA, Koopman MG, Krediet RT, Bos WJ: Blood pressure response to uncomplicated hemodialysis: the importance of changes in stroke volume. Nephron Clin Pract 2004;96:c82-c87.
3.
Palmer BF, Henrich WL: Recent advances in the prevention and management of intradialytic hypotension. J Am Soc Nephrol 2008;19:8-11.
4.
Dheenan S, Henrich WL: Preventing dialysis hypotension: a comparison of usual protective maneuvers. Kidney Int 2001;59:1175-1181.
5.
KDOQI: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45:S1-S153.
6.
Owen PJ, Priestman WS, Sigrist MK, Lambie SH, John SG, Chesterton LJ, McIntyre CW: Myocardial contractile function and intradialytic hypotension. Hemodial Int 2009;13:293-300.
7.
Mizumasa T, Hirakata H, Yoshimitsu T, Hirakata E, Kubo M, Kashiwagi M, Tanaka H, Kanai H, Fujimi S, Iida M: Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients: a 3-year prospective study. Nephron Clin Pract 2004;97:c23-c30.
8.
Shoji T, Tsubakihara Y, Fujii M, Imai E: Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004;66:1212-1220.
9.
Kersh ES, Kronfield SJ, Unger A, Popper RW, Cantor S, Cohn K: Autonomic insufficiency in uremia as a cause of hemodialysis-induced hypotension. N Engl J Med 1974;290:650-653.
10.
Poldermans D, Man in ‘t Veld AJ, Rambaldi R, Van Den Meiracker AH, Van Den Dorpel MA, Rocchi G, Boersma E, Bax JJ, Weimar W, Roelandt JR, Zietse R: Cardiac evaluation in hypotension-prone and hypotension-resistant hemodialysis patients. Kidney Int 1999;56:1905-1911.
11.
Kooman JP, Gladziwa U, Bocker G, van Bortel LM, van Hooff JP, Leunissen KM: Role of the venous system in hemodynamics during ultrafiltration and bicarbonate dialysis. Kidney Int 1992;42:718-726.
12.
Song JH, Park GH, Lee SY, Lee SW, Kim MJ: Effect of sodium balance and the combination of ultrafiltration profile during sodium profiling hemodialysis on the maintenance of the quality of dialysis and sodium and fluid balances. J Am Soc Nephrol 2005;16:237-246.
13.
Maynard JC, Cruz C, Kleerekoper M, Levin NW: Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med 1986;104:358-361.
14.
Depner TA: Assessing adequacy of hemodialysis: urea modeling. Kidney Int 1994;45:1522-1535.
15.
Canzanello VJ, Hylander-Rossner B, Sands RE, Morgan TM, Jordan J, Burkart JM: Comparison of 50% dextrose water, 25% mannitol, and 23.5% saline for the treatment of hemodialysis-associated muscle cramps. ASAIO Trans 1991;37:649-652.
16.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
17.
Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G: Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials 2000;21:502-525.
18.
Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR: Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The hemodialysis (HEMO) study. Kidney Int 1997;51:2013-2017.
19.
Miskulin DC, Athienites NV, Yan G, Martin AA, Ornt DB, Kusek JW, Meyer KB, Levey AS: Comorbidity assessment using the index of coexistent diseases in a multicenter clinical trial. Kidney Int 2001;60:1498-1510.
20.
Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
21.
Liu T, Liang KV, Rosenbaum A, Stephenson R, Pike F, Weissfeld L, Unruh ML: Peripheral vascular disease severity impacts health outcomes and health-related quality of life in maintenance hemodialysis patients in the HEMO study. Nephrol Dial Transplant 2012;27:2929-2936.
22.
Lilley JJ, Golden J, Stone RA: Adrenergic regulation of blood pressure in chronic renal failure. J Clin Invest 1976;57:1190-1200.
23.
Schroeder KL, Sallustio JE, Ross EA: Continuous haematocrit monitoring during intradialytic hypotension: precipitous decline in plasma refill rates. Nephrol Dial Transplant 2004;19:652-656.
24.
Tomita M, Malhotra D, Dheenan S, Shapiro JI, Henrich WL, Santoro TJ: A potential role for immune activation in hemodialysis hypotension. Ren Fail 2001;23:637-649.
25.
Arieff AI, Massry SG, Barrientos A, Kleeman CR: Brain water and electrolyte metabolism in uremia: effects of slow and rapid hemodialysis. Kidney Int 1973;4:177-187.
26.
Pappius HM, Oh JH, Dossetor JB: The effects of rapid hemodialysis on brain tissues and cerebrospinal fluid of dogs. Can J Physiol Pharmacol 1967;45:129-147.
27.
Kennedy AC, Linton AL, Eaton JC: Urea levels in cerebrospinal fluid after haemodialysis. Lancet 1962;1:410-411.
28.
Mann H, Stiller S: Urea, sodium, and water changes in profiling dialysis. Nephrol Dial Transplant 1996;11(suppl 8):10-15.
29.
Patel N, Dalal P, Panesar M: Dialysis disequilibrium syndrome: a narrative review. Semin Dial 2008;21:493-498.
30.
Henrich WL, Woodard TD, Blachley JD, Gomez-Sanchez C, Pettinger W, Cronin RE: Role of osmolality in blood pressure stability after dialysis and ultrafiltration. Kidney Int 1980;18:480-488.
31.
Rodrigo F, Shideman J, McHugh R, Buselmeier T, Kjellstrand C: Osmolality changes during hemodialysis. Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol. Ann Intern Med 1977;86:554-561.
32.
Port FK, Johnson WJ, Klass DW: Prevention of dialysis disequilibrium syndrome by use of high sodium concentration in the dialysate. Kidney Int 1973;3:327-333.
33.
Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M: Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 2004;19:785-796.
34.
Sang GL, Kovithavongs C, Ulan R, Kjellstrand CM: Sodium ramping in hemodialysis: a study of beneficial and adverse effects. Am J Kidney Dis 1997;29:669-677.
35.
Locatelli F, Stefoni S, Petitclerc T, Coli L, Di Filippo S, Andrulli S, Fumeron C, Frasca GM, Sagripanti S, Savoldi S, Serra A, Stallone C, Aucella F, Gesuete A, Scarlatella A, Quarello F, Mesiano P, Ahrenholz P, Winkler R, Mandart L, Fort J, Tielemans C, Navino C: Effect of a plasma sodium biofeedback system applied to HFR on the intradialytic cardiovascular stability. Results from a randomized controlled study. Nephrol Dial Transplant 2012;2012:4.
36.
Shimizu K, Kurosawa T, Sanjo T: Effect of hyperosmolality on vasopressin secretion in intradialytic hypotension: a mechanistic study. Am J Kidney Dis 2008;52:294-304.
37.
Mc Causland FR, Prior LM, Heher E, Waikar SS: Preservation of blood pressure stability with hypertonic mannitol during hemodialysis initiation. Am J Nephrol 2012;36:168-174.
38.
van der Zee S, Thompson A, Zimmerman R, Lin J, Huan Y, Braskett M, Sciacca RR, Landry DW, Oliver JA: Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int 2007;71:318-324.
39.
Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM: Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol 2011;22:1526-1533.
40.
McIntyre CW: Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif 2010;29:105-110.
41.
Flanigan M: Dialysate composition and hemodialysis hypertension. Semin Dial 2004;17:279-283.
42.
Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G: Association of achieved dialysis dose with mortality in the hemodialysis study: an example of ‘dose-targeting bias'. J Am Soc Nephrol 2005;16:3371-3380.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
